Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
Open Access
- 12 February 2025
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 15 (2) , 269
Abstract
Resistance to anti-PD-1 therapy in melanoma remains a major obstacle in achieving effective and durable treatment outcomes, highlighting the need to understand and address the underlying mechanisms. The first key factor is innate anti-PD-1 resistance signature (IPRES), an expression of a group of genes associated with tumor plasticity and immune evasion. IPRES promotes epithelial-to-mesenchymal transition (EMT), increasing melanoma cells’ invasiveness and survival. Overexpressed AXL, TWIST2, and WNT5a induce phenotypic changes. The upregulation of pro-inflammatory cytokines frequently coincides with EMT-related changes, further promoting a resistant and aggressive tumor phenotype. Inflamed tumor microenvironment may also drive the expression of resistance. The complexity of immune resistance development suggests that combination therapies are necessary to overcome it. Furthermore, targeting epigenetic regulation and exploring novel approaches such as miR-146a modulation may provide new strategies to counter resistance in melanoma.Keywords
Funding Information
- Carolina Zani Foundation (IMGEMI-COMBO (AMC))
This publication has 164 references indexed in Scilit:
- Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 studyAnnals of Oncology, 2024
- Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cellsCancer Cell, 2024
- Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidenceCancer Immunology, Immunotherapy, 2022
- Resistance to immune checkpoint inhibitors. Next steps and combinational approachesmemo - Magazine of European Medical Oncology, 2019
- Plasminogen activator inhibitor-1 in cancer researchBiomedicine & Pharmacotherapy, 2018
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaJAMA, 2016
- Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancerCancer Immunology, Immunotherapy, 2014
- Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanomaInternational Journal of Cancer, 2013
- Density of DC-LAMP+ mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factorCancer Immunology, Immunotherapy, 2007
- An Immunomodulatory Molecule of Symbiotic Bacteria Directs Maturation of the Host Immune SystemCell, 2005